Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data.

ABSTRACT:

Abstract

Objective

To estimate the effectiveness of vaccination with a monovalent covid-19 mRNA vaccine containing the omicron XBB.1.5 subvariant against severe covid-19 disease in Denmark, Finland, and Sweden.

Design

Target trial emulation based on registry data.

Setting

Denmark, Finland, and Sweden, 1 October 2023 to 21 April 2024.

Participants

Source population of 3 898 264 individuals eligible for vaccination with the XBB.1.5 containing covid-19 mRNA vaccine at the start of the study on 1 October 2023. Study cohort comprised 1 876 282 recipients of an XBB.1.5 containing vaccine during the study period matched with 1 876 282 non-recipients. Individuals were aged ≥65 years (mean age 75.4 years, standard deviation 7.4 years) and had received at least f

SUBMITTER: Andersson NW 

PROVIDER: S-EPMC11789462 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature